Open Door Salon
"There's probably about a 15 minute window on a certain Tuesday where you fit into the right window for an investor. You're too early. You're too late." Edwin Stone is the CEO of Cellular Origins, building robotic manufacturing for cell therapy. Erik Digman Wiklund is the CEO of Circio Holding, developing next-gen gene therapies. Both actually got funded in a market where almost no one does. Two CEOs on why investors move in herds, why you can't do vaccines right now, and why China now has more cell therapy trials than the US. In Today's Episode: * "There's a 15 minute window on a certain Tuesday": the absurd reality of biotech funding * Investors move in herds: in vivo CAR-T gets everything * "You can't do vaccines right now": the political climate * "Falling between the cracks": too early, then too late * China now has the majority of cell therapy trials * Platform vs asset: why platforms fell out of favor * Cost of Phase 1 has gone up 4x in less than 10 years * Europe is half the cost of the US * What a well-funded company looks like in 2028 Timestamps: (00:00) Cold Open: "The 15 Minute Window Becomes Five"(05:00) The Funding Environment: In Vivo CAR-T Gets Everything(10:00) Investors Move in Herds(15:00) "You Can't Do Vaccines Right Now"(20:00) Platform vs Asset(25:00) China Has the Majority of Trials(30:00) "Falling Between the Cracks"(35:00) The 15 Minute Window(40:00) What Well-Funded Looks Like in 2028(45:00) Europe Is Half the Cost SHOW NOTES Edwin Stone — CEO, Cellular Origins🔗 Cellular Origins: https://www.cellularorigins.com/ [https://www.cellularorigins.com/] Erik Digman Wiklund — CEO, Circio Holding🔗 Circio: https://www.circio.com/ [https://www.circio.com/]
18 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de Open Door Salon!